Monkeypox Cases: Update as of August 23, 2022

Update as of August 23, 2022, following reports of monkeypox cases in France and around the world. The next update will be released on August 31, 2022.

In early May 2022, cases of monkeypox with no direct link to travel to Central or West Africa—where the virus is present—or to people returning from travel were reported in Europe and around the world. Since then, the disease has been subject to enhanced surveillance in France and across Europe. As of August 23, 3,421 biologically confirmed cases have been recorded in France.

Update on the Situation in France

As of 6:00 p.m. on August 23, 2022, 3,421 biologically confirmed cases had been recorded in France.

As part of its regular process to verify the quality of indicators, the Agency has identified 350 cases that had not yet been entered into the databases since the last update published on the Agency’s website on Thursday, August 18. The total number of confirmed cases published today therefore includes a data catch-up, which should not be interpreted as an exceptional increase in the number of cases. Spread out over time, this catch-up does not alter the observed trends. It has no impact on patient information or care.

The distribution of confirmed cases by region of residence (or by region of reporting when the region of residence is unknown) is shown in Figure 1. The Île-de-France region has the highest number of cases (2,110, or 62%), followed by Occitanie (277 cases), Auvergne-Rhône-Alpes (231 cases), and Provence-Alpes-Côte d’Azur (212 cases). Nineteen cases reside abroad.

For 1,005 confirmed cases (29.3%), the region of residence was unknown and was replaced by the region of reporting. The vast majority of confirmed cases recorded to date are adult males (1.4% are women). Eight children under the age of 15 have been reported. Adult cases have a median age of 36 years; 25% of adult cases are under 30 years of age and 25% are between 43 and 77 years of age. Among the cases for which information was available at the time of notification, 65 (3%) are known to have been hospitalized due to their Monkeypox infection.

In France, no deaths have been reported to date.

The main characteristics of the 39 confirmed cases in women are as follows: their median age is 27 years (ranging from 18 to 61 years). The majority reside in the Île-de-France region.

The circumstances of these women’s exposure are difficult to determine. Among the 22 women for whom information is available, 5 reported having been in contact with a person infected with monkeypox within the 3 weeks preceding the onset of symptoms. This contact occurred within the household or living environment (living with a family member or spouse). Two women reported occupations that could have exposed them to the virus (healthcare worker and hospitality industry). For the others, interview data did not allow for the identification of a presumed mode of transmission.

The distribution of confirmed cases by date of symptom onset (when known) is shown in Figure 2. The date of symptom onset for these cases ranges from May 7, 2022, to August 18, 2022. Due to reporting delays, data from the most recent weeks have not been consolidated.

The reports received do not always mention the date of symptom onset. As an alternative to this information, the distribution of cases by date of reporting is shown in Figure 3.

These data appear to show that the number of infections peaked in late June/early July and that since then the number of cases has been trending downward. Nevertheless, we must remain very cautious, as the summer period may have led to delays in diagnosis and reporting. Similarly, some people may not have sought medical care. Other countries with which we exchange data, particularly in Europe, are also observing a slowdown or even a decrease in the number of new cases reported in recent weeks. This trend will need to be confirmed in the coming weeks.

Figure 1. Biologically confirmed cases of monkeypox (n=3,402 cases) by region of residence (or by region of reporting when the region of residence is unknown), France, May–August 2022 (data as of August 23, 2022 – 6:00 p.m.)

Figure 1. Cas confirmés biologiquement de variole du singe (n=3 402 cas) par région de résidence (ou par région de signalement lorsque la région de résidence est inconnue), France, mai-août 2022 (données au 23/08/2022 – 18h00)

Figure 2. Biologically confirmed cases of monkeypox (n=2,415 cases) by week of symptom onset, France, May–August 2022 (data as of August 23, 2022 – 6:00 p.m.).

Figure 2. Cas confirmés biologiquement de variole du singe (n=2 415 cas) par semaine de début des symptômes, France, mai-août 2022 (données au 23/08/2022 – 18h00).
The data for the past few weeks (shown in gray) is not yet fully finalized.

Figure 3. Biologically confirmed cases of monkeypox (n = 3,402 cases) by week of reporting, France, May–August 2022 (data as of August 23, 2022 – 6:00 p.m.).

Figure 3. Cas confirmés biologiquement de variole du singe (n= 3 402 cas) par semaine de signalement, France, mai-août 2022 (données au 23/08/2022 – 18h00).
The data for the past week (shown in gray) are not fully consolidated (the dip in reported cases observed in week 28 (July 11–17) can be attributed to the July 14 holiday).

Information and Prevention Initiatives

Given what has been observed in Europe regarding the disease, targeted communication was quickly implemented for MSM. The website sexosafe.fr, dedicated to the sexual health of MSM, is regularly updated with a summary of current knowledge on the subject and prevention measures. Poster, radio, and digital campaigns provide information to the public, complementing on-the-ground initiatives. Since June 17, the digital campaign has generated nearly 729,877 clicks on banners and over 656,402 visits to the Sexosafe website.

All information on vaccination is updated weekly on the pages for the general public and for healthcare professionals (accessible without a login) on the Vaccination-info-service website.

Prevention efforts are continuously adapted to the evolving situation and the current state of knowledge.

To make information more accessible to vulnerable people in precarious situations, a visual resource—translated into 6 languages and developed in collaboration with professionals working with these individuals—is available on Sante Publique France.

The MOBCO Newsletter No. 7, developed in collaboration with frontline workers, compiles a series of questions and answers on the topic of monkeypox. It is intended for professionals and volunteers working with people in precarious situations.

In France, ongoing surveillance of monkeypox through the mandatory reporting system has been strengthened, and information and alert messages are being sent to healthcare professionals. Discussions are also continuing with other European countries, the WHO, and the ECDC.

Monkeypox Info Service: A helpline to answer questions about monkeypox

The “Monkeypox Info Service” hotline is available daily from 8 a.m. to 11 p.m. at the toll-free number 0 801 90 80 69 (free calls and services; anonymous and confidential). This service is responsible for supporting prevention messages and protective measures, providing information on symptoms, treatments, and vaccination, and offering advice and referrals to care services.

Since the hotline opened in mid-July, 6,400 calls have been handled by the Monkeypox Info Service.

  • 547 calls were handled in week 33 (compared to 846 in week 32)

  • There has been a steady decline in the number of daily calls since Wednesday, August 10, 2022.

  • The proportion of calls from women is rising: it now accounts for 17% of calls, compared to 13% in week 32.

  • Île-de-France remains the top region for calls, but the percentage has dropped by 6% compared to week 32 (47% vs. 53%). The Auvergne-Rhône-Alpes and Occitanie regions each account for 10% of calls. There has been a 3% increase in calls from the Hauts-de-France region (7% in week 33 vs. 4% in week 32).

  • Overall, there have been no major changes in the types of calls. However, there has been a 4% increase in the percentage of calls regarding transmission risks (risk of becoming infected and/or risk of infecting one’s partner): 21% vs. 17% in week 32.

Preventive Vaccination Against Monkeypox

In response to the spread of the Monkeypox virus, the High Authority for Health, following a referral from the Directorate General for Health, recommended in its opinion dated July 7, 2022, that preventive vaccination be offered to groups most at risk of exposure to the virus.

Regarding the rollout of the vaccination, 103,372 doses of third-generation vaccine had been delivered by the Agency to the regions as of August 23, 2022. Deliveries are primarily made on a weekly basis.

Since July 11, 2022, in addition to individuals who have had high-risk contact with an infected person, individuals meeting the criteria established by the HAS may schedule an appointment to be vaccinated throughout the country:

  • Men who have sex with men and report having multiple sexual partners.

  • Transgender individuals reporting multiple sexual partners.

  • Sex workers.

  • Professionals working in venues where sexual services are provided.

Vaccination may also be considered on a case-by-case basis for healthcare professionals who care for infected individuals.

To learn more about vaccination and access to vaccination sites:

Smallpox B (Mpox)

thematic dossier

Smallpox B (Mpox), formerly known as monkeypox, is a rare viral infectious disease caused by the monkeypox virus and transmitted primarily from rodents to humans, and then from person to person,...

Safe Sex

HIV and STI prevention, testing, and sexual orientation—the Sexosafe website addresses issues related to sexuality among men.

Vaccination Information Service

What are vaccines for? How do they work? At what age should children be vaccinated? Vaccination-info-service.fr answers the most frequently asked questions about vaccination. A separate...